Высокодозная химиотерапия при лимфоме

Высокодозная химиотерапия с трансплантацией аутологичных кроветворных стволовых клеток при лимфоме Ходжкина. Десятилетний опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России

Полный текст:

Ключ. слова

Об авторах

Список литературы

1. Абдурахманов Д.Т., Абузарова Г.Р., Аль-Ради Л.С. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. проф. И.В. Поддубной и проф. В.Г. Савченко. М.: Типография ООО «Буки Веди», 2016. 324 с. [Abdurakhmanov D.T., Abuzarova G.R., Al-Radi L.S. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Edited by prof. I.V. Poddubnya and prof. V.G. Savchenko. M .: Tipografiya Buki Vedi, 2016. 324 p. (In Russ.)].

2. Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013:14(10):943–52.

3. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.

4. Thomas R.K., Re D., Zander T. et al. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 2002;13(Supl.4):147–52.

5. Linch D., Winfield D., Goldstone A. et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomized trial. Lancet 1993;341:1051–4.

6. Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compaired with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomized trial. Lancet 2002;359(9323):2065–71.

7. Josting A., Franklin J., May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20(1):221–30.

8. Ljungman P., Bregni M., Brune M. et al. Allogenic and autologous transplantation for haematologocal disease, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219–34.

9. Perales M.A., Ceberio I., Armand P. et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21(6):971–83.

10. NCCN Guidelines for Hodgkin Lymphoma. Version 1.2017.

11. Moscowitz C.H., Kewalramani T., Nimer S.D. et al. Effectivness of high-dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645–52.

12. Sirohi B., Cunningham D., Powles R. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–9.

13. Provencio M., Sánchez A., Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat Rev 2014;40(3):457–64.

14. Gopal A.K., Chen R., Smith S.E. et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125(8):1236–43.

15. Armand P., Shipp M.A., Ribrag V. et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016. pii: JCO673467. [Epub ahead of print].

16. Younes A., Santoro A., Shipp M. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283–94.

17. Moskowitz C.H., Nimer S.D., Zelenets A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–23.

18. Phillips J.K., Spearing R.L., Davies J.M. et al. VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol 1990;27:161–3.

19. ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann Oncol 1995;6:167–72.

20. Colwill R., Crump M., Couture F. et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396–402.

21. Rodriguez M.A., Cabanillas F.C., Hagemeister F.B. et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609–11.

22. Aparicio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10:593–5.

23. Martin A., Femandez-Jimenez M.C., Caballero M.D. et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001;113:161–71.

24. Josting A., Rudolph C., Reiser M. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:1628–35.

25. Abali H., Urün Y., Oksüzoğlu B. et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401–6.

26. European Society for Blood and Marrow Transplantation Annual Report, 2016.

Понравилась статья? Поделиться с друзьями: